Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (190)	11/13/1997 11:42:00 PM
From: Dulane U. Ponder	Respond to of 4474

Thanks for the update, John. Seems like the Ariad thread has been a little despondent lately judging from the dwindling posts. I still like Ariad and am holding on to it (of course, I have to now if I want to see my money again in this lifetime). Thanks again.

To: John Dwyer who wrote (190)	12/11/1997 2:42:00 AM
From: John Dwyer	Read Replies (5) \| Respond to of 4474

Cell Genesis published a report in the Dec. 9th issue of PNAS where they "successfully prevented neurodegeneration in an animal model for Parkinson's disease utilizing adeno-associated viral (AAV) gene therapy. AAV vectors were used to deliver the gene for glial cell line-derived neurotrophic factor (GDNF) to the region of the brain affected in Parkinson's disease resulting in stable expression of the GDNF gene measured out to ten weeks, the duration of the study" mktnews.nasdaq.com. These reports give me more confidence in this approach. I look forward to seeing some proof-of-principle reports out of Ariad over the next few months. John